Striant System Boosts Bone Density in American Men with Osteoporosis: 3-Year Study

Introduction

Osteoporosis, a condition characterized by decreased bone density and increased risk of fractures, is a significant health concern for American males. As men age, the natural decline in testosterone levels can exacerbate this condition. The Striant Testosterone Buccal System, a novel form of testosterone replacement therapy, has been proposed as a potential treatment to improve bone health in this population. This article presents the findings of a three-year longitudinal study investigating the effects of the Striant system on bone density in American men with osteoporosis.

Study Design and Methodology

The study involved 200 American males aged 50 to 75 years, all diagnosed with osteoporosis. Participants were randomly assigned to either the treatment group, receiving the Striant Testosterone Buccal System, or the control group, receiving a placebo. Bone density measurements were taken at baseline, 12 months, 24 months, and 36 months using dual-energy X-ray absorptiometry (DEXA) scans. Additionally, serum testosterone levels and markers of bone turnover were assessed at each time point.

Results: Bone Density Changes

After 12 months, the treatment group demonstrated a significant increase in bone mineral density (BMD) at the lumbar spine compared to the control group (p < 0.05). This trend continued through the 24-month and 36-month follow-ups, with the treatment group showing a mean BMD increase of 4.2% at the lumbar spine and 3.1% at the femoral neck by the end of the study. In contrast, the control group experienced a mean BMD decrease of 1.8% at the lumbar spine and 1.2% at the femoral neck over the same period.

Serum Testosterone and Bone Turnover Markers

The Striant Testosterone Buccal System effectively maintained serum testosterone levels within the normal range throughout the study duration. Participants in the treatment group exhibited a significant reduction in markers of bone resorption, such as C-terminal telopeptide of type I collagen (CTX), and an increase in markers of bone formation, such as procollagen type I N-terminal propeptide (PINP). These findings suggest that the Striant system not only improves bone density but also positively influences bone metabolism.

Clinical Implications and Future Directions

The results of this longitudinal study provide compelling evidence that the Striant Testosterone Buccal System can significantly improve bone density in American males with osteoporosis. This treatment may offer a valuable option for men at risk of fractures due to low bone mass. However, further research is needed to assess the long-term safety and efficacy of the Striant system, as well as its impact on fracture rates and overall quality of life.

Limitations and Considerations

While the study demonstrates promising results, several limitations should be acknowledged. The sample size, although adequate, may not fully represent the diverse population of American males with osteoporosis. Additionally, the study did not assess the impact of the Striant system on fracture incidence, which is a critical endpoint in osteoporosis management. Future studies should aim to include larger and more diverse cohorts, as well as incorporate fracture risk assessment as a primary outcome measure.

Conclusion

In conclusion, the Striant Testosterone Buccal System shows significant potential in improving bone density and positively influencing bone metabolism in American males with osteoporosis. The findings of this three-year longitudinal study highlight the importance of considering testosterone replacement therapy as part of a comprehensive approach to managing osteoporosis in this population. As research continues to evolve, the Striant system may emerge as a valuable tool in the fight against osteoporosis and its associated complications in American men.

Contact Us Today For A Free Consultation

Name *

Email *

Phone *

Your Program *HGH TherapyHGH InjectionsTestosterone InjectionsCo-Created ProgramTestosterone TherapyAt Home HRT ProgramSermorelin InjectionsIpamorelinPeptidesWeight ManagementHuman Growth HormoneShort Height TherapyGender DysmorphiaBlood ServicesTesamorelinOther

Your State *United StatesAlabamaAlaskaArizonaArkansasCaliforniaColoradoConnecticutDelawareFloridaGeorgiaHawaiiIdahoIllinoisIndianaIowaKansasKentuckyLouisianaMaineMarylandMassachusettsMichiganMinnesotaMississippiMissouriMontanaNebraskaNevadaNew HampshireNew JerseyNew MexicoNew YorkNorth CarolinaNorth DakotaOhioOklahomaOregonPennsylvaniaPuerto RicoRhode IslandSouth CarolinaSouth DakotaTennesseeTexasUtahU.S. Virgin IslandsVermontVirginiaWashingtonWashington,DCWest VirginiaWisconsinWyomingCanada

Select Age (30+ only) *Over 2930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475+

* Required

Dear Patient,

Once you have completing the above contact form, for security purposes and confirmation, please confirm your information by calling us.

Please call now: 1-800-380-5339.

Welcoming You To Our Clinic, Professor Tom Henderson.